QUOTE AND NEWS
Benzinga  Nov 17  Comment 
In a report published Monday, Bank of America analyst Derik de Bruin reiterated a Buy rating on Mettler-Toledo International (NYSE: MTD), and raised the price target from $290.00 to $320.00. In the report, Bank of America noted, “On 11/10/14...
SeekingAlpha  Aug 23  Comment 
By Poonam A. Arora: Investment Conclusion. Initial data read outs from the Epizyme (NASDAQ:EPZM) EPZ-6438 Phase I dose escalation study were robust. The drug showed early indications of activity in two NHL patients, there was a lack of significant...
SeekingAlpha  Jul 25  Comment 
Mettler-Toledo International (NYSE:MTD) Q2 2014 Earnings Call July 24, 2014 5:00 pm ET Executives Mary T. Finnegan - Head of Investor Relations and Treasurer Olivier A. Filliol - Chief Executive Officer, President and Director ...
newratings.com  Jun 2  Comment 
CANBERA (dpa-AFX) - ARIAD Pharmaceuticals Inc.'s (ARIA) approved cancer drug Iclusig has demonstrated anti-tumor activity in patients with refractory metastatic and/or unresectable gastrointestinal stromal tumors in a phase II trial. Iclusig...
SeekingAlpha  May 11  Comment 
Start Time: 17:00 End Time: 17:53 Mettler Toledo International Inc. (MTD) Q1 2014 Earnings Conference Call May 8, 2014 05:00 PM ET Executives Olivier A. Filliol - CEO William P. Donnelly - Head of Finance, Supply Chain and IT ...
SeekingAlpha  May 8  Comment 
The following audio is from a conference call that will begin on May 08, 2014 at 17:00 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Forbes  Apr 10  Comment 
In just 14 years, the International Automobile Exhibition in Beijing and Shanghai has become one of the premier auto shows in the world.




 
TOP CONTRIBUTORS

Mettler-Toldedo International develops precision instruments primarily for the life science industry (pharmaceutical and biotech companies, as well as independent research organizations); food and beverage producers; food retailers, and chemical, specialty chemicals and cosmetics companies. It focuses primarily on laboratory and industrial instruments. The company sells products primarily in Europe, the Americas, and Asia. Its global presence represents strong growth opportunities, however their markets can be unpredictable. Also due to the large capital expenditure of its instruments MTD's revenues experience seasonality and can fluctuate according to capital spending patterns of customers, tending to be larger in the fourth quarter of each year.[1]

Business Growth

For 2010 the company reported net sales of $1,968 million, an increase of 14% over 2009. The increase in sales was attributed to improved global economic conditions and deferral of product replacements by customers during 2009.[1]

Trends and Forces

Economic conditions in emerging markets represent growth opportunities, but can be unpredictable

Although the majority of MTD's sales are in developed countries it is quickly growing sales in emerging markets. For example, in 2010 sales in China accounted for just under $300 million of yearly sales. In addition to China the company has sales in other emerging markets of Asia, Latin America, and Eastern Europe. Though these countries represent strong growth opportunities they can be unpredictable and with varying amount of currency risk and local legal and regulatory requirements.[1]

MTD's revenues can fluctuate according to capital spending patterns of customers

MTD's customers often stock up on lab consumables and equipment at the end of the year, when funding is abundant (for example, NIH funding is distributed to labs towards the end of the calendar year). MTD's revenues thus fluctuate throughout the year and are strongest in the last quarter of the calendar year. NIH funding is not completely stable, either - economic pressures may result in a stagnation of NIH funding, which has been growing at 2-3% in the past few years, but is not expected to increase in the near future. MTD's customers from academic and government research labs are directly affected by the limitations of NIH grant funding; a lack of funding results in fewer laboratory product and equipment purchases and adversely affects MTD's sales revenues.[1]

Competition



References

  1. 1.0 1.1 1.2 1.3 Mettler-Toledo International 2011 10k
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki